会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • Phosphorus compounds, processes for their manufacture, and their use
    • 磷化合物,其制造方法及其用途
    • US4885285A
    • 1989-12-05
    • US773707
    • 1985-09-09
    • Gerhard BaschangAlbert HartmannHans HirtBohumir LucasPeter Wirz
    • Gerhard BaschangAlbert HartmannHans HirtBohumir LucasPeter Wirz
    • A61K31/66A61K31/685A61P31/12C07F9/09
    • A61K31/66C07F9/091
    • Cephalin derivatives of the formula I ##STR1## in which R.sup.1 and R.sup.2 each represents, independently of the other, hydrogen or lower alkyl, R.sup.3 represents hydrogen, lower alkoxycarbonyl, carbamoyl or free or protected carboxy, R.sup.4 represents hydrogen or an aliphatic, aromatic, aromatic-aliphatic or cycloaliphatic radical, W represents hydrogen and Z represents a 1,2-dihydroxyethyl, 2-hydroxyethyl or hydroxymethyl group in which at least one hydroxy group is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.6-30 -alcohol and in which the other hydroxy group, if present, is free, esterified by an aliphatic C.sub.2-30 -carboxylic acid or etherified by an aliphatic C.sub.1-30 -alcohol, or W represents hydroxymethyl or a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -alcohol and Z represents a hydroxymethyl group that is esterified by an aliphatic C.sub.6-30 -carboxylic acid or etherified by an aliphatic C.sub.6-30 -alcohol, and their salts are suitable for the prophylaxis and treatment of virus infections in warm-blooded animals.
    • 式I的头孢氨酸衍生物(I)其中R 1和R 2各自独立地代表氢或低级烷基,R 3表示氢,低级烷氧基羰基,氨基甲酰基或游离或保护的羧基,R 4表示氢或脂族基 ,芳香族,芳香族 - 脂肪族或脂环族基,W表示氢,Z表示1,2-二羟乙基,2-羟乙基或羟甲基,其中至少一个羟基被脂肪族C 6-30 - 羧酸酯化,或通过 脂肪族C 6-30 - 醇,其中另一个羟基(如果存在的话)是游离的,用脂肪族C 2-30-羧酸酯化或用脂族C 1-10醇醚化,或W表示羟甲基或羟甲基 其被脂肪族C 6-30醇酯化,Z表示被脂肪族C 6-30 - 羧酸酯化或通过脂肪族C 6-30醇醚化的羟甲基,其盐适用于预防 治疗温血动物中的病毒感染。
    • 3. 发明授权
    • Peptide derivatives
    • 肽衍生物
    • US4439425A
    • 1984-03-27
    • US385594
    • 1982-06-07
    • Lajos TarcsayBruno KamberJaroslav StanekGerhard BaschangAlbert Hartmann
    • Lajos TarcsayBruno KamberJaroslav StanekGerhard BaschangAlbert Hartmann
    • C07K1/113A61K38/00A61P37/04C07J41/00C07K5/083C07K5/103C07K7/06C07K14/245A61K37/00
    • C07K7/06C07K14/245C07K5/081C07K5/1013A61K38/00
    • The present invention relates to new lipopeptides and in particular to compounds of either of the formulae ##STR1## wherein R.sub.1 and R.sub.2 each represent a saturated or unsaturated aliphatic or mixed aliphatic-cycloaliphatic hydrocarbon radical which has 11-21 C atoms and which is also optionally substituted by oxygen functions, R.sub.3 represents hydrogen or the radical R.sub.1 --CO--O--CH.sub.2 --, where R.sub.1 has the same meaning, R.sub.1 ' is a saturated or unsaturated aliphatic hydrocarbon radical of at least 9 C atoms, which is optionally substituted at one of the C atoms non adjacent to the sulfur atom by a free hydroxyl group or a hydroxyl group esterified with a monobasic carboxylic acid and which is optionally interrupted in the C atoms chain by one or more oxygen atoms, and which hydrocarbon is optionally substituted by a maximum of 2 cycloaliphatic hydrocarbon radicals having 5-8 ring C atoms, or R.sub.1 ' is the radical --CO--R.sub.1 ", wherein R.sub.1 " represents a saturated or unsaturated aliphatic or mixed aliphatic-cycloaliphatic hydrocarbon radical of 11-21 C-atoms and which is optionally interrupted in the C atoms chain by oxygen atoms, and X represents an amino acid with free esterified or amidated carboxyl group, or an amino acid sequence of 2-10 aliphatic amino acids, the terminal carboxyl group of which is free or in the ester or amide form, the amino acids being naturals ones in the case of compounds of formula (1).
    • 本发明涉及新的脂肽,特别是涉及式(I)* = R ** = R或S或R / S中的任一个的化合物(I')n = 1,2 * = R / S或R或S,其中R 1和R 2各自表示饱和或不饱和的具有11-21个C原子的脂族或混合的脂族 - 脂环族烃基,并且也可任选被氧官能团取代,R 3表示氢或基团R 1 - CO-O-CH 2 - ,其中R 1具有相同的含义,R 1'是至少9个C原子的饱和或不饱和脂族烃基,其任选地在不与硫原子相邻的C原子之一被自由基 羟基或用一元羧酸酯化的羟基,其任选地在C原子链中被一个或多个氧原子中断,并且该烃任选被具有5-8个环C原子的最多2个脂环族烃基取代 ,或者R1'是-CO-R1“基团,其中R1”表示 是11-21个C原子的饱和或不饱和脂族或混合脂族 - 脂环族烃基,其任选在C原子链中被氧原子中断,X表示具有游离酯化或酰胺化羧基的氨基酸,或 2-10脂肪族氨基酸的氨基酸序列,其末端羧基是游离的或呈酯或酰胺形式,氨基酸在式(1)化合物的情况下是天然的。
    • 4. 发明授权
    • Acylated sugar derivatives, processes for their manufacture, and their
use
    • 酰化糖衍生物,其制备方法及其用途
    • US4640911A
    • 1987-02-03
    • US739269
    • 1985-05-29
    • Gerhard BaschangAlbert HartmannOskar Wacker
    • Gerhard BaschangAlbert HartmannOskar Wacker
    • C07K9/00A61K31/70C08G18/08
    • C07K9/005
    • There are described sugar derivatives of the formula I ##STR1## that have immuno-stimulating action and that contain as inventive element at least one radical A.sup.1 or A.sup.2. These radicals A.sup.1 and A.sup.2, which may be constituents of the radicals R.sup.1, R.sup.2, R.sup.4, R.sup.6, R.sup.9, R.sup.10 or R.sup.12 according to formula I, are defined as follows:A.sup.1 represents lower alkanoyl that is substituted by aryl, heteroaryl or heteroarylthio and that may be additionally substituted by an ethylene radical which, with the above-mentioned aryl or heteroaryl substituent, forms a five-membered ring or represents ortho- or ortho/meta-substituted aroyl. A.sup.2 represents lower alkoxy substituted by aryl heteroaryl or heteroarylthio.Also described are processes for the manufacture of the compounds of the formula I and novel intermediates.
    • 描述具有免疫刺激作用的式I(I)的糖衍生物,并且含有至少一个基团A1或A2的本发明元素。 这些基团A1和A2可以是根据式I的基团R 1,R 2,R 4,R 6,R 9,R 10或R 12的组分,其定义如下:A1代表被芳基,杂芳基或杂芳硫基取代的低级烷酰基, 其可以另外被乙烯基团取代,其中上述芳基或杂芳基取代基形成五元环或代表邻位或邻位/间位取代的芳酰基。 A2代表被芳基杂芳基或杂芳硫基取代的低级烷氧基。 还描述了制备式I化合物和新型中间体的方法。
    • 6. 发明授权
    • Acylated sugar derivatives, processes for their manufacture, and their
use
    • 酰化糖衍生物,其制备方法及其用途
    • US4711879A
    • 1987-12-08
    • US928493
    • 1986-11-07
    • Gerhard BaschangAlbert HartmannOskar Wacker
    • Gerhard BaschangAlbert HartmannOskar Wacker
    • A61K38/00A61K39/39A61P37/04C07K1/113C07K9/00A61K31/70C08G18/08
    • C07K9/005
    • There are described sugar derivatives of the formula I ##STR1## that have immuno-stimulating action and that contain as inventive element at least one radical A.sup.1 or A.sup.2. These radicals A.sup.1 and A.sup.2, which may be constituents of the radicals R.sup.1, R.sup.2, R.sup.4, R.sup.6, R.sup.9, R.sup.10 or R.sup.12 according to formula I, are defined as follows:A.sup.1 represents lower alkanoyl that is substituted by aryl, heteroaryl or heteroarylthio and that may be additionally substituted by an ethylene radical which, with the above-mentioned aryl or heteroaryl substituent, forms a five-membered ring or represents ortho- or ortho/meta-substituted aroyl. A.sup.2 represents lower alkoxy substituted by aryl, heteroaryl or heteroarylthio.Also described are processes for the manufacture of the compounds of the formula I and novel intermediates.
    • 描述具有免疫刺激作用的式I(I)的糖衍生物,并且含有至少一个基团A1或A2的本发明元素。 这些基团A1和A2可以是根据式I的基团R 1,R 2,R 4,R 6,R 9,R 10或R 12的组分,其定义如下:A1代表被芳基,杂芳基或杂芳硫基取代的低级烷酰基, 其可以另外被乙烯基团取代,其中上述芳基或杂芳基取代基形成五元环或代表邻位或邻位/间位取代的芳酰基。 A2代表被芳基,杂芳基或杂芳硫基取代的低级烷氧基。 还描述了制备式I化合物和新型中间体的方法。
    • 10. 发明授权
    • Antibiotic preparations having increased effectiveness, processes for
their manufacture and method for increasing the antibiotic action of
antibiotics
    • 具有增加效力的抗生素制剂,其制备方法和增加抗生素抗生素作用的方法
    • US4414204A
    • 1983-11-08
    • US226966
    • 1981-01-21
    • Lajos TarcsayGerhard BaschangAlbert HartmannJaroslav Stanek
    • Lajos TarcsayGerhard BaschangAlbert HartmannJaroslav Stanek
    • C07H13/00A61K38/00A61K38/14A61K39/39A61P37/04C07K1/06C07K1/113C07K9/00C07K14/52C07K14/53C07K14/535A61K37/02A61K31/71C07C103/52
    • C07K9/005
    • The invention relates to pharmaceutical preparations that contain an antibiotic and a muramylpeptide of the formula I or a salt thereof, to processes for their manufacture and to a method for increasing the antibiotic effectiveness of antibiotics. ##STR1## In the formula I, X represents carbonyl or carbonyloxy, R.sub.1 represents optionally substituted alkyl or aryl, R.sub.2, R.sub.3, R.sub.4 and R.sub.6 represent hydrogen or lower alkyl, R.sub.5 represents hydrogen, optionally substituted lower alkyl, cycloalkyl, aryl or nitrogen-containing heterocyclyl, or R.sub.4 and R.sub.5 together represent also C.sub.3 -C.sub.4 alkylene, R.sub.7 represents hydrogen or free, esterified or amidated carboxyl, one of the radicals A.sub.1 and A.sub.2 represents a radical of the formula II and the other of the radicals A.sub.1 and A.sub.2 represents optionally substituted or functionally modified hydroxy or amino. ##STR2## In the formula II, T represents NH or O, Y represents an optionally substituted alkylene group that can also be interrupted by oxycarbonyl or iminocarbonyl, W represents hydrogen and Z represents an optionally esterified or etherified 1,2-dihydroxyethyl or 2-hydroxyethyl group, or W and Z represent an optionally esterified or etherified hydroxymethyl group.
    • 本发明涉及含有抗生素和式I的胞壁酰胺或其盐的药物制剂及其制备方法以及提高抗生素抗生素效力的方法。 (I)在式I中,X表示羰基或羰氧基,R 1表示任选取代的烷基或芳基,R 2,R 3,R 4和R 6表示氢或低级烷基,R 5表示氢,任选取代的低级烷基,环烷基,芳基 或含氮杂环基,或者R4和R5一起也代表C3-C4亚烷基,R7代表氢或游离的酯化或酰胺化的羧基,基团A1和A2之一代表式II的基团和基团A1中的另一个 且A2表示任选取代的或官能改性的羟基或氨基。 (II)在式II中,T表示NH或O,Y表示也可被氧羰基或亚氨基羰基间隔的任选取代的亚烷基,W表示氢,Z表示任选酯化或醚化的1,2-二羟乙基 或2-羟乙基,或W和Z表示任选酯化或醚化的羟甲基。